Please login to the form below

Not currently logged in
Email:
Password:

Europe delays EMA relocation decision

Will resolve the issue in November, one month later than expected

EMAThe decision on which country will host Europe’s pharma regulator once the UK leaves the European Union has been postponed by one month.

Currently based in London, the European Medicines Agency (EMA) is now expected to learn later this year in November where it will be moved to.

The decision will be taken at a meeting of the heads of state or government from the 27 states that will make up the EU after March 29, 2019, and its delay has prompted pharma to voice its concern.

European trade body EFPIA acknowledged the complexity of the Brexit negotiations, but argued in a statement “medicines constitute a special case in term of securing swift agreement on both sides”.

“It is imperative for the safeguarding of public health that we ensure future alignment between the UK and EU regulatory regimes in order to maintain capacity, processes and timeframes for the introduction of new medicines for patients,” it added.

Echoing this Dr Virginia Acha, executive director of research, medicine and innovation at the UK’s ABPI, said: “It will be critical to avoid divergence and duplication of regulatory regimes, so that patient safety is not put at risk."

The EU’s November meeting will also see the post-Brexit location decided of the European Banking Authority (EBA), which must leave London too.

EU member states can bid to host both, but - with the EMA’s fate to be decided first - the country that wins the right to the medicines regulator cannot then continue with its bid for the EBA.

Countries that have so far thrown their hats into the ring for the EMA contest include Copenhagen, Barcelona, Lisbon and Dublin - any more that are interested have until July 31 to submit their offer.

Article by
Dominic Tyer

26th June 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
5 ways that lockdowns and restrictions could be affecting our allergies
Over this last year, lockdowns and restrictions have led to changes in the day-to-day environments for people across the world. For Allergy Awareness week, we wanted to explore some of...